Karyopharm Therapeutics Inc Earnings

The next earnings date for Karyopharm Therapeutics Inc is August 10, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Karyopharm Therapeutics Inc Earnings

Report Date	Estimated Earnings Per Share
08/10/2026	$-1.42

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Karyopharm Therapeutics Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
05/14/2026	Before Market	$-1.02	30.00%
02/12/2026	Before Market	$-2.22	-9.13%
11/03/2025	Before Market	$-3.82	-19.63%
08/11/2025	Before Market	$-4.32	-3.34%
05/12/2025	After Market	$-2.77	35.04%
02/19/2025	Before Market	$-3.60	10.00%
11/05/2024	Before Market	$-3.90	3.03%
08/06/2024	Before Market	$2.25	149.25%
05/08/2024	Before Market	$-4.80	6.03%
02/29/2024	Before Market	$-5.40	-13.96%
11/02/2023	Before Market	$-4.50	-5.04%
08/02/2023	Before Market	$-4.35	16.92%
05/04/2023	Before Market	$-4.50	20.12%
02/15/2023	Before Market	$-6.45	-19.42%
11/03/2022	After Market	$-6.75	21.99%
08/04/2022	Before Market	$-9.30	4.02%
05/05/2022	Before Market	$-7.95	17.65%
01/10/2022	Before Market	$6.90	187.47%
11/03/2021	Before Market	$-10.35	-0.47%
08/05/2021	Before Market	$-10.65	7.07%
05/03/2021	Before Market	$-11.55	-6.17%
02/11/2021	Before Market	$-8.85	2.29%
11/02/2020	After Market	$-10.95	1.01%
08/04/2020	Before Market	$-9.45	-6.31%
05/05/2020	Before Market	$-11.70	-10.23%
02/13/2020	Before Market	$-11.40	-11.21%
11/04/2019	Before Market	$-10.05	20.50%
08/06/2019	Before Market	$-10.65	29.29%
05/09/2019	Before Market	$-16.35	-22.69%
02/28/2019	Before Market	$-14.40	-10.86%
11/08/2018	Before Market	$-11.85	13.27%
08/07/2018	Before Market	$-9	27.02%
05/10/2018	Before Market	$-11.70	-22.98%
03/15/2018	Before Market	$-12	-20.66%
11/02/2017	Before Market	$-9.75	1.20%
08/08/2017	Before Market	$-9.60	2.93%
05/04/2017	Before Market	$-10.65	-4.36%
03/16/2017	Before Market	$-9.75	3.88%
11/07/2016	After Market	$-10.35	16.17%
08/04/2016	Before Market	$-12.60	-8.54%
05/09/2016	Before Market	$-11.25	0.83%
03/14/2016	Before Market	$-12.15	3.35%
11/09/2015	Before Market	$-12.75	4.21%
08/10/2015	Before Market	$-13.80	-17.14%
05/11/2015	Before Market	$-11.10	0.96%
03/11/2015	After Market	$-11.85	-19.16%
11/10/2014	Before Market	$-9.15	-14.64%
08/07/2014	Before Market	$-8.25	-8.93%
05/07/2014	After Market	$-6.90	3.36%
03/05/2014	Before Market	$-30	-471.11%

More About Karyopharm Therapeutics Inc

Website

https://www.karyopharm.com

Country

USA

Full Time Employees

228

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

“Karyopharm Therapeutics Inc Earnings” Can Refer to the Karyopharm Therapeutics Inc Earnings Date

Some people say “Karyopharm Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Karyopharm Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Karyopharm Therapeutics Inc Stock on the Earnings Date

If you own Karyopharm Therapeutics Inc stock (KPTI) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Karyopharm Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Karyopharm Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Karyopharm Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Karyopharm Therapeutics Inc earnings or anything else related to the stock market.